anti- LAG-3 antibody

Este producto es parte de LAG3 - lymphocyte activating 3
Product Graph
Contáctenos para saber el precio

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
anti- LAG-3 antibody
category
Primary Antibodies
provider
FineTest
reference
FNab04676
tested applications
ELISA, WB, IP

Documents del producto

Instrucciones
Descargar
Data sheet

Product specifications

Category
Primary Antibodies
Immunogen Target
lymphocyte-activation gene 3
Host
Rabbit
Reactivity
human,mouse,rat
Recommended Dilution
WB: 1:500-1:1000; IP: 1:500-1:1000
Clonality
polyclonal
Conjugation
Unconjugated
Isotype
IgG
Observed MW
54kd,60-65kd
Purity
≥95% as determined by SDS-PAGE
Purification
Immunogen affinity purified
Size 1
100µg
Form
liquid
Tested Applications
ELISA, WB, IP
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
UniProt ID
P18627
Gene ID
3902
Alias
Lymphocyte activation gene 3 protein ,CD223,LAG-3,FDC
Background
Antibody anti-LAG3
Status
RUO
Note
This product is for research use only.

LAG3 (lymphocyte-activation gene 3), also known as CD223, is a cell surface protein that plays a critical role as an immune checkpoint inhibitor. It functions as a negative regulator of T cell activity and is predominantly expressed on activated T cells, regulatory T cells (Tregs), and natural killer (NK) cells. LAG-3 belongs to the immunoglobulin (Ig) superfamily and is structurally similar to CD4, although it performs an inhibitory rather than activating function. Its primary ligand is the major histocompatibility complex (MHC) class II, and it binds with much higher affinity than CD4, providing it with strong immunoregulatory capabilities. As an immune checkpoint receptor, LAG-3 is critical for maintaining immune homeostasis and preventing autoimmune reactions by moderating immune responses. Its expression is upregulated during chronic infections and in cancer, often contributing to T cell exhaustion, a state in which T cells progressively lose function due to prolonged antigen exposure. This makes LAG-3 a therapeutic target in immuno-oncology and chronic infection therapies. The blockade of LAG-3 has shown potential in restoring T cell function, thereby enhancing anti-tumor and anti-pathogen immune responses.

Related Products

EH1083

Human LAG3(Lymphocyte activation gene 3 protein) ELISA Kit

Ver Producto
FNab04676

anti- LAG-3 antibody

Ver Producto
P1753

Recombinant Human LAG3

Ver Producto